Melanoma detection study using PET scan in healthy volunteers
Part of Cancer, Skin clinical trials.
This study tests a new PET imaging method that tracks how fat is used in the body, which may help find melanoma earlier. Healthy volunteers are needed to set a baseline for this new technique.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- Your body mass index (BMI) is between 18 and 28.
- You can have an IV and are not afraid of needles or blood.
- You do not have serious heart, kidney, lung, or mental health conditions.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a new kind of PET/CT scan to take detailed pictures of solid tumors such as melanoma, liver, lung, breast, pancreatic, or ovarian cancer. The scan might help doctors find cancer more clearly.
This trial tests a new type of PET scan that may find cancer more clearly and quickly than current scans. It's for people with advanced melanoma that has spread and cannot be removed by surgery.
This trial tests a new type of PET/CT scan that uses a special tracer (called ⁶⁸Ga-FXX489) to help find and diagnose cancers. It is for people who are strongly suspected to have cancer and want to see if this new imaging method can help their doctors learn more about their disease.
This trial uses a special PET scan to take pictures of certain solid tumors. The scan uses a new dye that may help doctors see the tumors more clearly. You may be eligible if you have one of the listed cancers and are between 18 and 75 years old with good daily function.
This trial tests a new radioactive tracer called 68Ga-SFB6-ZN01 for PET/CT scans in people with suspected or confirmed solid tumors. It aims to see if this tracer can help find cancer or detect recurrence after treatment.
This study checks an “interim” whole-body scan (PET-CT) partway through treatment to see how well anti-PD-1 immunotherapy (nivolumab or pembrolizumab) is working for advanced melanoma. It may help doctors better understand early treatment response and guide next steps.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.